Yahoo Finance

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Yahoo Finance

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Nasdaq

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
The Business Journals

Larimar Therapeutics' stock price tumbles on mixed study results for lead drug candidate

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Larimar Therapeutics reports ...
MedCity News

FDA places clinical hold on Larimar’s rare disease drug after deaths in monkey study

The clinical hold means that Bala Cynwyd, Pennsylvania-based Larimar can’t proceed with further tests of the drug, CTI-1601, in humans, including a study that was expected to start in the second half ...
BNamericas

Dominican Republic promotes rare earths and Larimar while consolidating key projects

The Dominican Republic combines rare earth exploration, Larimar valorization, and projects like Pueblo Viejo to consolidate a diversified mining industry ...